A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 (SUN101) in Subjects With Moderate to Severe COPD

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 (SUN101) in Subjects With Moderate to Severe COPD

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Ipratropium bromide; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms GOLDEN-1
  • Sponsors Sunovion Respiratory Development
  • Most Recent Events

    • 22 May 2013 Tolerability results presented at the 109th International Conference of the American Thoracic Society.
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 03 Sep 2012 Results have been presented at the 2012 European Respiratory Society Annual Congress according to an Elevation Pharmaceuticals media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top